Clinical Trial: Exploration of the Efficacy and Safety of Different - Cycle Neoadjuvant Treatment with Rekan Trastuzumab in Early - stage HER2 - positive Breast Cancer: A Two - Cohort, Exploratory Study (China)

China, Aug. 13 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Exploration of the Efficacy and Safety of Different - Cycle Neoadjuvant Treatment with Rekan Trastuzumab in Early - stage HER2 - positive Breast Cancer: A Two - Cohort, Exploratory Study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129981

Registration Time: 2026/08/12

Type: Interventional study

Primary Sponsor: Fujian Cancer Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=332508

Published by HT Digital Content Services with permission from Health Daily Digest....